Radionuclide myocardial perfusion imaging in predischarge risk stratification of medically treated patients with non-ST elevation acute coronary syndrome
- Rabih R Azar, MD, MSc, FACC
Rabih R Azar, MD, MSc, FACC
- Professor of Medicine
- St. Joseph University School of Medicine
- Gary V Heller, MD, PhD, FACC, MASNC
Gary V Heller, MD, PhD, FACC, MASNC
- Section Editor — Noninvasive Cardiac Imaging
- Division of Cardiovascular Medicine Morristown Medical Center
The use of antithrombotic and anti-ischemic medications has markedly improved the short-term outcome in patients with non-ST elevation acute coronary syndrome (NSTEACS). At present, almost all patients with NSTEACS are managed with early cardiac catheterization and, if appropriate, revascularization. (See "Coronary angiography and revascularization for unstable angina or non-ST elevation acute myocardial infarction".)
A minority of patients with NSTEACS are at low short-term risk  and can be treated medically since they may not benefit from revascularization . This is also true for an occasional patient at intermediate risk . However, some of these patients have ongoing ischemia and may develop new coronary events after hospital discharge. (See "Risk factors for adverse outcomes after non-ST elevation acute coronary syndromes".)
The possible value of radionuclide myocardial perfusion imaging in risk stratification of medically treated patients with NSTEACS will be reviewed here. Previous studies of such patients, performed before the widespread use of early revascularization, illustrated the persistent risk following medical therapy:
●In the TIMI III registry, the incidence of MI or cardiac death at six week follow-up was 3.2 and 3.1 percent, respectively .
●In the TIMI IIIB trial, the one year non-fatal MI and cardiac death rate were 8.8 and 4.3 percent, respectively .
- Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284:835.
- Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879.
- Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).
- Stone PH, Thompson B, Anderson HV, et al. Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. JAMA 1996; 275:1104.
- Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995; 26:1643.
- Madsen JK, Stubgaard M, Utne HE, et al. Prognosis and thallium-201 scintigraphy in patients admitted with chest pain without confirmed acute myocardial infarction. Br Heart J 1988; 59:184.
- Brown KA. Prognostic value of thallium-201 myocardial perfusion imaging in patients with unstable angina who respond to medical treatment. J Am Coll Cardiol 1991; 17:1053.
- Marmur JD, Freeman MR, Langer A, Armstrong PW. Prognosis in medically stabilized unstable angina: early Holter ST-segment monitoring compared with predischarge exercise thallium tomography. Ann Intern Med 1990; 113:575.
- Jain D, Thompson B, Wackers FJ, Zaret BL. Relevance of increased lung thallium uptake on stress imaging in patients with unstable angina and non-Q wave myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI)-IIIB Study. J Am Coll Cardiol 1997; 30:421.
- Zhu YY, Chung WS, Botvinick EH, et al. Dipyridamole perfusion scintigraphy: the experience with its application in one hundred seventy patients with known or suspected unstable angina. Am Heart J 1991; 121:33.
- Younis LT, Byers S, Shaw L, et al. Prognostic value of intravenous dipyridamole thallium scintigraphy after an acute myocardial ischemic event. Am J Cardiol 1989; 64:161.
- Stratmann HG, Younis LT, Wittry MD, et al. Exercise technetium-99m myocardial tomography for the risk stratification of men with medically treated unstable angina pectoris. Am J Cardiol 1995; 76:236.
- Stratmann HG, Tamesis BR, Younis LT, et al. Prognostic value of predischarge dipyridamole technetium 99m sestamibi myocardial tomography in medically treated patients with unstable angina. Am Heart J 1995; 130:734.
- Brown KA, Heller GV, Landin RS, et al. Early dipyridamole (99m)Tc-sestamibi single photon emission computed tomographic imaging 2 to 4 days after acute myocardial infarction predicts in-hospital and postdischarge cardiac events: comparison with submaximal exercise imaging. Circulation 1999; 100:2060.
- Mahmarian JJ, Shaw LJ, Filipchuk NG, et al. A multinational study to establish the value of early adenosine technetium-99m sestamibi myocardial perfusion imaging in identifying a low-risk group for early hospital discharge after acute myocardial infarction. J Am Coll Cardiol 2006; 48:2448.